Guaiol is a woody sesquiterpene alcohol best known in the AromaForge archive as a major marker of guaiacwood and blue cypress style oils, with additional presence in agarwood and white-cypress-derived materials. Compared with many trace constituents, guaiol has a usable direct literature base: public identity data are straightforward, archive oil occurrence is strong, and multiple preclinical papers report insecticidal, antiparasitic, and cancer-biology activity in laboratory models. That said, the evidence remains preclinical rather than clinical, so AromaForge should frame guaiol as a well-established woody marker constituent with promising but non-human study data.
Chemical identity and composition
NIST lists guaiol as C15H26O, CAS 489-86-1, and records aliases including alpha-guaiol, champacol, and guaiac alcohol. In archive context it is one of the dominant sesquiterpene alcohols in guaiacwood and blue cypress style oils, contributing woody-balsamic character and functioning as a chemotype marker rather than only a trace note.
Aroma and practical use
- Use the recorded woody, balsamic, rosy, tea-like, dry, rose-like descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2014 PubMed-indexed study identified guaiol as the main isolated active from a fraction of Volutella citrinella and described it as a naturally occurring insecticidal sesquiterpene.
This is one of the clearest direct isolated-compound activity papers for guaiol in a non-human bioassay.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2018 antileishmanial paper reported in the PubMed snippet that guaiol and Aloysia gratissima essential oil were active against Leishmania amazonensis, and that guaiol did not induce nitric oxide in resting macrophages while inhibiting nitric oxide production in lipopolysaccharide-stimulated macrophages.
The accessible snippet is useful both for activity and for cautious mechanism framing around macrophage nitric oxide modulation.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2023 PubMed snippet reported that (-)-guaiol induced immunogenic cell death in non-small cell lung cancer models and suppressed tumor growth in vivo while increasing dendritic cell activation and T-cell infiltration.
This expands guaiol's laboratory evidence base, but it remains cancer-model research rather than consumer-relevant human evidence.
This experimental finding does not establish benefit, dose or safety in people using this blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
The live public evidence located here is stronger for identity and preclinical activity than for modern fragrance-safety review specific to isolated guaiol.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
The antileishmanial study snippet reported that guaiol was safe for macrophages up to the tested in vitro level, but this should not be generalized to human topical safety.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
No constituent-specific RIFM safety assessment or human dermal-limit source for isolated guaiol was verified in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
dose_dependent_arthropod_toxicity
The insecticidal paper supports guaiol acting directly against storage-pest larvae in a laboratory bioassay.
This experimental finding does not establish benefit, dose or safety in people using this blend.
nitric_oxide_modulation_in_activated_macrophages
The antileishmanial study reported that guaiol inhibited nitric oxide production in lipopolysaccharide-stimulated macrophages while not inducing nitric oxide in resting macrophages.
This experimental finding does not establish benefit, dose or safety in people using this blend.
autophagy_and_apoptosis_linked_tumor_cell_effects
Cancer-model papers and linked summaries describe (-)-guaiol as affecting RAD51 and autophagy-associated pathways that culminate in apoptosis or immunogenic cell death in NSCLC models.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (7)
- No human clinical literature specific to isolated guaiol was verified in this pass.
- A modern public fragrance-safety assessment for isolated guaiol was not confirmed here.
- Most direct guaiol findings are from insect, parasite, or cancer-biology models rather than fragrance-use studies.
- 2026-07-13 verification pass: web search for IFRA/RIFM dermal limit and sensitization data for guaiol (CAS 489-86-1) returned only chemical-supplier and general IFRA-framework pages, no constituent-specific dermal limit or sensitization determination; prior dermal_limit_pct (20) and sensitizing (true) were unsourced placeholders and have been corrected to null.
- 2026-07-13 second-pass verification: tried two different angles from the RIFM/IFRA web search already attempted - (1) searched specifically for a Tisserand & Young Essential Oil Safety 2nd ed. monograph entry for guaiol and found only general book/publisher pages with no accessible constituent-specific monograph text; (2) searched cannabis-terpene topical-safety literature (guaiol is also a well-known Cannabis terpene) and found only consumer cannabis-education pages plus a related finding that another cannabis terpene, beta-caryophyllene, can induce dermatitis on repeated high-concentration topical mouse exposure - this is a different compound and was not used as evidence for guaiol itself. No authoritative constituent-specific dermal limit, sensitization determination, or Tisserand monograph text for guaiol was located; dermal_limit_pct, sensitizing, and penetration_enhancer remain unverified.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.